Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension of bexicaserin in developmental and epileptic encephalopathy
NL-OMON60344Phase 3Active, not recruiting
- Sponsor
- Longboard Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bexicaserin in epileptic encephalopathy, sponsored by Longboard Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Safety laboratory parameters and 5 more. Started Aug 2026; status: active, not recruiting.
02
Drugs
bexicaserin
03
Conditions
epileptic encephalopathy
Beyond the preview
Go deeper on NL-OMON60344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60344.